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Abstract   
We hypothesized that key antiproliferative target genes for the vitamin D receptor (VDR) 
were repressed by an epigenetic mechanism in prostate cancer cells resulting in apparent 
hormonal insensitivity. To explore this possibility we examined nuclear receptor co-repressor 
expression in a panel of non malignant and malignant cell lines and primary cultures, and 
found frequently elevated SMRT co-repressor mRNA expression often associated with 
reduced sensitivity to 1α,25-dihydroxyvitamin D3 [1α,25(OH)2D3]. For example, PC-3 and 
DU-145 prostate cancer cell lines had 1.8- and 2- fold increases in SMRT mRNA relative to 
normal PrEC cells (p<0.05). Similarly 10/15 primary tumour cultures (including 3 matched to 
normal cells from the same donors) had elevated SMRT mRNA levels; generally NCoR1 and 
Alien were not as commonly elevated. Co-repressor proteins often have associated histone 
deacetylases (HDAC) and reflectively the antiproliferative action of 1α,25(OH)2D3 can be 
‘restored’ by co-treatment with low doses of HDAC inhibitors such as trichostatin A (TSA, 
15 nM) to induce apoptosis in prostate cancer cell lines.  
To decipher the transcriptional events that lead to these cellular responses we 
undertook gene expression studies in PC-3 cells after co-treatment of 1α,25(OH)2D3 plus TSA 
after 6 hr. Examination of known VDR target genes and cDNA microarray analyses revealed 
co-treatment of 1α,25(OH)2D3 plus TSA co-operatively upregulated 8 (out of 1176) genes, 
including MAPK-APK2 and GADD45α. MRNA and protein time courses and inhibitor 
studies confirmed these patterns of regulation. Subsequently we knocked-down SMRT levels 
in PC-3 cells using a small interfering RNA (siRNA) approach and found that GADD45α 
induction by 1α,25(OH)2D3  alone became very significantly enhanced. The same distortion of 
gene responsiveness, with repressed induction of GADD45α was found in primary tumour 
cultures compared and to matched peripheral zone (normal) cultures from the same donor. 
These data demonstrate that elevated SMRT levels are common in prostate cancer 
cells, resulting in suppression of target genes associated with antiproliferative action and 
apparent 1α,25(OH)2D3-insensitivity. This can be targeted therapeutically by combination 
treatments with HDAC inhibitors.  
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Introduction 
Prostate epithelial cells express multiple members of the nuclear receptor (NR) superfamily. 
These receptors act as ligand-activated transcription factors to regulate genes essential for 
regulation of proliferation and differentiation. The vitamin D receptor (VDR) typifies this 
class of transcription factors by associating with vitamin D response elements (VDRE) in the 
promoter/enhancer region of target genes as part of multimeric, repressive or activating 
complexes.  
Proliferation and differentiation of normal prostate epithelial cells is acutely regulated 
in vitro and in vivo by 1α,25(OH)2D3 (Konety et al. 1996; Peehl et al. 1994) thereby 
justifying clinical trials in prostate cancer patients (Beer et al. 2003). However prostate cancer 
cells display a spectrum of sensitivities to the antiproliferative action of 1α,25(OH)2D3 
(reviewed in (Chen & Holick 2003; Krishnan et al. 2003; Peehl & Feldman 2003). Reflective 
of an antiproliferative role, epidemiological studies have now linked the incidence of prostate 
cancer to low serum levels of 25(OH)D3 as a result of either diet or environment, and specific 
VDR polymorphisms have been correlated with cancer susceptibility (Hanchette & Schwartz 
1992; Ingles et al. 1998). Collectively, such data implicate 1α,25(OH)2D3  with a protective 
action against uncontrolled prostate growth; that initiation or progression of prostate cancer 
may relate to reduced dietary intake and/or cellular resistance to the antiproliferative effects of 
1α,25(OH)2D3.   
The molecular mechanisms for 1α,25(OH)2D3-insensitivity in prostate cancer are as 
yet unclear.  We and others have demonstrated that the VDR is neither mutated nor is there a 
clear relationship between VDR expression and growth inhibition by 1α,25(OH)2D3 (Miller et 
al. 1997; Zhuang et al. 1997). Indeed, the  PC-3 and DU 145 prostate cancer cell lines are not 
significantly inhibited by physiologically relevant doses of 1α,25(OH)2D3 and consistent with 
this response, antiproliferative gene targets are not modulated (Campbell et al. 2000; 
Campbell et al. 1997). The lack of an antiproliferative response is not reflected by an overall 
suppression of the capacity of these cells to perceive 1α,25(OH)2D3. VDR transactivation is 
sustained or even enhanced, as measured by induction of the highly 1α,25(OH)2D3-inducible 
CYP24 gene [encoding 25(OH)D3-24-hydroxylase – the 1α,25(OH)2D3  metabolising 
enzyme] (Miller et al. 1995).  
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 To resolve why prostate cancer cells appear to loose sensitivity to the antiproliferative 
action of 1α,25(OH)2D3  we have considered epigenetic mechanisms which regulate promoter 
access.  Nuclear receptors exist in a complexes that are in a dynamic balance between the apo, 
ligand-free state associated with co-repressor and the holo, ligand-bound state associated with 
co-activator (Germain et al. 2002; Hermanson et al. 2002). In the absence of 1α,25(OH)2D3 
the VDR associates in a gene repression complex which contains co-repressor proteins such 
as NCoR1, SMRT and Alien, and associated histone deacetylases (HDAC) (Polly et al. 2000; 
Guenther et al. 2001; Yu et al. 2003). These complexes maintain the histone N-terminal ‘tails’ 
in a charged state tightly associated with DNA, thereby maintaining a locally closed 
chromatin structure and suppressing transcription of target genes (Belandia & Parker 2003 
Guenther et al (2001)]. Ligand binding induces activation which has been demonstrated for 
related nuclear receptors to include ordered promoter-specific cyclical rounds of complex 
assembly, gene transactivation, disassembly and proteosome degradation of receptor 
(Metivier et al. 2003; Reid et al. 2003b). Central to this are ligand-induced conformational 
changes which promotes association between the VDR and co-activator complexes containing 
proteins such as SRC-1, NCoA-62, GRIP-1 and DRIP factors (Zhang et al. 2001; Oda et al. 
2003; Rachez et al. 2000; Belandia & Parker 2003; Rachez & Freedman 2000),.  The 
antagonistic actions of these opposing complexes are controlled temporally and spatially to 
determine the boundaries between heterochromatin and euchromatin and gene promoter 
responsiveness.  
The cell-specific position of the dynamic balance between apo and holo states is 
determined by both ligand availability and the unique mileu of co-activator and co-repressors 
which combine to yield gene specific responses (Hermanson et al. 2002). The equilibrium is 
targeted for disruption in malignancy by aberrant co-activator and co-repressor function 
resulting in both gain and loss of nuclear receptor function. For example, increased co-
activator expression enhances the transcriptional activity of androgens and estrogens in breast 
and prostate cancer, respectively (Gnanapragasam et al. 2001; Feldman & Feldman 2001; 
Planas-Silva et al. 2001; Kawashima et al. 2003; Jiang et al. 2003b; Hudelist et al. 2003; 
Kollara et al. 2001). Similarly RARα-fusion proteins in acute promyelocytic leukaemia bind 
co-repressors more aggressively than wild type receptors and thereby suppress transactivation 
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of antiproliferative target genes by all trans retinoic acid (Grignani et al. 1998; Lin et al. 
1998).  
Therefore we have proposed that VDR signaling is not abrogated in prostate cancer 
cells but it is skewed by epigenetic mechanisms to repress key antiproliferative gene targets. 
Previously we showed that co-treatment of three prostate cancer cell lines (LNCaP, PC-3 and 
DU 145) with 1α,25(OH)2D3 plus HDAC inhibitors, either trichostin A (TSA) or sodium 
butyrate, resulted in additive and synergistic inhibition of proliferation associated with 
apoptosis (Rashid et al. 2001a). For the current study we hypothesised that an imbalance in 
the co-activator/co-repressor balance is selectively distorting promoter responsiveness of 
VDR antiproliferative target genes resulting in 1α,25(OH)2D3-insensitivity. We have now 
examined VDR and co-repressor levels in cell lines and primary cultures, dissected the effects 
of 1α,25(OH)2D3 plus TSA on gene expression patterns to identify antiproliferative pathways 
that are suppressed in malignancy and we have also examined the effects of knocking-down 
SMRT levels using a small interfering RNA approach.  
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Materials and Methods 
 
1α,25(OH)2D3 and HDAC inhibitors  
1α,25(OH)2D3 (generous gift of Dr. Milan R. Uskokovic, Hoffman La Roche, Nutley, NJ 
07110, U.S.A.) and TSA (Sigma, Poole, U.K.) were all stored as 1 mM stock solutions in 
ethanol at –20oC. SB203580, an inhibitor of p38 activation, (CalBiochem, Nottingham, UK), 
was prepared fresh as required as a 1 mM stock solution in DMSO. 
 
Cell culture 
Normal prostate epithelial cells (PrEC), as a non-transformed epithelial counter-part were 
purchased and cultured in PrEGM media (Clonetics, Wokingham, UK) according to 
manufacturer’s instructions. These cells had a finite lifespan passage time but during the 
course of the current study they had a doubling time approximately equal to that of the 
prostate cancer cell line  PC-3 cells (~24 hr), obtained from the American Type Culture 
Collection (ATCC, Rockville, MD). PC-3 cCells were maintained in RPMI 1640 medium 
(Gibco-BRL, Paisely, UK), supplemented with 100 units/ml penicillin, 100 µg/ml 
streptomycin and 10% fetal bovine serum (Gibco-BRL,), and passaged by trypsinising with 
0.25% trypsin-EDTA (Gibco-BRL). All cells were grown at 37oC in a humidified atmosphere 
of 5% CO2 in air.  
 
Primary cultures  
Tissues dissected from radical prostatectomy specimens were processed for primary culture of 
prostatic epithelial cells according to previously described methods (Peehl 2004). None of the 
patients had received prior chemical, hormonal or radiation therapy.  Histological assessment 
was performed as described (Schmid & McNeal 1992). Normal peripheral zone (PZ) and  
benign prostatic hyperplasia (BPH) were established from tissue with no cancer present in 
adjacent tissue sections. Cancer cultures (CA) were established from adenocarcinomas of 
varying Gleason grade listed in Table 1.  Each cell strain was ascribed a number and serially 
passaged and cells in secondary or tertiary passages were used for clonal growth assays or 




Proliferation assays  
The action of individual agents alone and in combination was examined using a 
bioluminescent technique to measure changes in cellular ATP (ViaLight HS, LumiTech, 
Nottingham, U.K.) with previously optimised conditions according to the manufacturer’s 
instructions (Rashid et al. 2001a).  Briefly, cells were plated in 96- well, white-walled, tissue 
culture-treated plates (Fisher Scientific Ltd., Loughborough, U.K.) (LNCaP, PC-3 and DU 
145 at 2 x 103 cells/well; PrEC at 3.5 x 103 cells/well). Growth media containing varying 
concentrations of TSA, 1α,25(OH)2D3, or SB203580 was added to a final volume of  100 
µl/well and plates were incubated for 96 h, with re-dosing after 48 h.  After the incubation 
period, 100 µl of nucleotide releasing reagent was added to each well and cells were left for 
30 minutes at room temperature. Liberated ATP was quantitated by adding 20 µl of ATP 
monitoring reagent (containing luciferin and luciferase) and measuring luminescence with a 
microplate luminometer (Berthold Detection Systems, Fisher Scientific Ltd.). ATP levels 
were recorded in relative luciferase units and growth inhibition was expressed as a percentage 
of control. 
Clonal proliferation assays were used to evaluate responses of primary cultures to 
1α,25(OH)2D3.  Each 60-mm tissue culture dish, coated with collagen and containing 5 ml of 
serum-free medium [Peehl et al (2002)] and vehicle or 1α,25(OH)2D3, was inoculated with 
500 cells per dish.  After 10 days of incubation, cells were fixed with formalin and stained 
with crystal violet [Peehl et al (2002)]. Total cell growth was measured with an Artek image 
analyzer (Dynatech, Chantilly, VA, USA).   
 
Extraction of RNA and reverse transcription  
PrEC, LNCaP, PC-3 and DU 145 cells were seeded at a density of 2x104/cm2 and allowed to 
grow for 36 h to ensure that cells were in mid-exponential phase upon treatment. Cells were 
harvested or dosed by adding cycloheximide (20 µg/ml) (Sigma-Aldrich), 1α,25(OH)2D3 
and/or TSA as indicated with fresh media and incubating for various times. Total RNA was 
extracted using the GenElute RNA extraction system (Sigma-Aldrich) according to 
manufacturer’s instructions. Primary cultures were serially passaged and grown to 80% 
confluency in standard serum-free medium.  Cells were fed and dosed with 1α,25(OH)2D3  as 
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indicated one day, prior to isolation of total RNA using the Qiagen RNeasy Midi kit (Qiagen, 
Palo Alto, CA, USA).  
For real time reverse transcription-polymerase chain reaction (RT-PCR), cDNA was 
prepared from 1 µg of total RNA by reverse transcription with Mu-MLV (Promega 
Southampton, UK) at 42°C for 60 min in the presence of 100 mM Tris-HCl, pH 9.0, 500 mM 
KCl, 2 mM MgCl2, 100 pM  random hexamers (Pharmacia, Pisacataway, NJ), 2 mM dNTP 
and 20 U RNAsin (Promega) in a 20 µl reaction volume.   
  
Real-Time Quantitative RT-PCR (Q-RT-PCR) 
Expression of specific mRNAs was quantitated using the ABI PRISM 7700 Sequence 
Detection System. Each sample was amplified in triplicate wells in 25 µl volumes containing 
1x TaqMan Universal PCR Master Mix [3 mM Mn(OAc)2, 200 µM dNTPs, 1.25 units 
AmpliTaq Gold polymerase, 1.25 units AmpErase UNG], 3.125 pmoles FAM-labelled 
TaqMan probe and 22.5 pmoles primers. All reactions were multiplexed with pre-optimized 
control primers and VIC- labeled probe for 18S ribosomal RNA (PE Biosystems, Warrington, 
UK). Primer and probe sequences are given in Table 2. Reactions were cycled as follows: 
50°C for 2 min, 95°C for 10 min; then 44 cycles of 95°C for 15 sec and 60°C for 1 min.  
Data were expressed as Ct values (the cycle number at which logarithmic PCR plots 
cross a calculated threshold line) and used to determine δCt values (δCt = Ct of the target 
gene minus Ct of the housekeeping gene). The data was transformed through the equation 2-
δδCt to give fold changes in gene expression. To exclude potential bias due to averaging of 
data all statistics were performed with δCt values. Measurements were carried out a minimum 
of three times each in triplicate wells for cell lines and once each in triplicate wells for 
primary material.  
 
cDNA microarray analyses  
PC-3 cells were seeded at a density of 2x104/cm2 in T75 flasks and allowed to grow for 36 h. 
Fresh medium was added with the following treatments: 1α25(OH)2D3 (100 nM) and/or TSA 
(15 nM) or left untreated as control. After 6 h total RNA was isolated as indicated above, 
DNAse treated and resuspended at a concentration of 2.5 µg/µl. From these RNA stocks 2 µl 
was used for subsequent generation of radiolabelled probe according to the manufacture’s 
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instructions (Clontech, Wokingham, UK). Clontech Human 1.2 cDNA arrays were incubated 
overnight with radiolabelled probe. After careful washing the membrane was exposed to film 
(Kodak, XOMAT) overnight and for 72 h. Images were scanned and the relative difference in 
the intensity of the signals analysed using the Clontech AtlasImage 1.5 software, which with 
reference to internal controls, pre-set limits at which differences in signal intensity and/or fold 
differences (greater than 2-fold) were reported.  
Repeat experiments involved stripping the membranes (which were checked to ensure 
zero signal) and reprobing with radio labelled probes prepared with mRNA isolated from 
repeat treatments of cells as described above. Tables of differences for each individual and 
combined treatment were compared to control. For each of the treatments the adjusted 
difference in the intensity of signals for gene targets that were reported in both experiments 
were averaged to generate the change in the mean adjusted intensity (∆MAI). Mean fold 
differences were only calculated where the basal level of target was detectable. Only genes 
that were reported as modulated in the same manner in both experiments were included in the 
results. 
 
Western immunoblot analysis  
PC-3 cells were seeded at a density of 2x104/cm2 in T75 flasks and allowed to grow for 36 h. 
Fresh medium was added with the following treatments: 1α25(OH)2D3 (100 nM) and/or TSA 
(15 nM) or left untreated as control. Whole cell lysates were prepared at indicated time points 
and Western immunoblot analysis performed.  Briefly, 30 µg of total protein for each sample 
was electrophoresed through an sodium dodecyl sulfate (SDS)-polyacrylamide gel, 
transferred onto PVDF membrane (Immobilon-P; Millipore, Bedford, MA) and blocked with 
TBS-T containing 5% milk powder for 1 h.  For detection of GADD45α, a rabbit polyclonal 
antibody (C-20, Santa Cruz Biotechnology, USA) was diluted 1:500.  The secondary 
antibody, donkey anti-rabbit-HRP conjugate (Amersham, Amersham, UK) was diluted 
1:1000.  Proteins were detected using ECL (Amersham) and autoradiography.  To ensure even 
loading and transfer of protein, membranes were washed for 15 min with TBS-T and 
incubated with a 1/10000 dilution of primary mouse monoclonal β-actin antibody (AC-15, 
Sigma-Aldrich).  An anti-mouse-HRP secondary antibody (Binding Site, UK) was used at 
1:2000, and signals developed with ECL and autoradiography as described above. To quantify 
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the relative changes in protein levels, densitometry analysis was performed on the 
autoradiographs and values normalised to β-actin levels.  
  
Small interfering RNA to target SMRT. 
SiRNA fragments (22mers) were generated in vitro using a Dicer generation system 
according to the manufacturer’s protocol (Gene Therapy Systems, San Diego, CA). Briefly, a  
650 bp region from the human SMRT gene sequence corresponding to 112 to 762 was 
amplified using the following primers containing T7 promoter sequences;   
FS:  5’ – gcgtaatacgactcactatagggagacgggctcctggagtaccagc – 3’ and   
RV: 5’ – gcgtaatacgactcactatagggagagctccacctggggccccagg – 3’. This was subsequently 
cloned into the pGEM T easy vector (Promega), using the multiple cloning sites to allow for 
sequencing, large scale harvest. Digestion with ECoR1 released a pure concentrated template 
for in vitro translation with primers containing T7 recognition sequences to generate double 
stranded mRNA. This was subsequently cleaved with recombinant human Dicer enzyme to 
generate a pool of 22mers which cover the region targeted in the 5’prime region of the SMRT 
gene. Five hundred ng of purified double stranded RNA 22mers were transfected into each 
well (2x105 cells/well in 24-well plates) for 12 hrs. Cells were then left for a further 72 hr to 
allow gene silencing and subsequently treated with 1α,25(OH)2D3 (100 nM) for 6 hr and total 
RNA was harvested and Q-RT-PCR for SMRT and target genes was undertaken as above. 
 
Statistical analysis  
The interactions of two compounds were assessed by measuring the mean of either 
1α25(OH)2D3  or TSA acting alone or in combination (Campbell et al. 1998).  The mean 
observed combined effect was compared to the individual effects of the agents added 
together, using the Student’s t-test. Classification of the effects were as follows: strong 
additive effects were those with an experimental value significantly greater than the 
predicted value, additive effects were those where the experimental value did not 
significantly differ from the predicted value, sub-additive effects were those where the 
experimental value was significantly less than the predicated value. All other analyses 
were compared using the Student’s t-test.  
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Results 
SMRT mRNA levels are elevated in prostate cancer cell lines and primary cultures. 
We reasoned that cancer cells can escape proliferative control from nuclear receptors, such as 
VDR, by elevating co-repressor expression. We therefore measured the mRNA levels of VDR 
and the nuclear co-repressors SMRT, NCoR1 and Alien in primary cultures of cancers (E-
CA-1, 2, 3, 4, 5, 6, 9, 10, 11, 12, 15, mean age of 55.5), benign prostatic hyperplasia (E-BPH-
1, E-BPH-2, mean age 61 ) compared to the mean of seven normal peripheral zones cultures 
(E-PZ-1 to 7, mean age of 55) (Figure 1A), three matched tumour and normal pairs from the 
same donor (E-CA-7, 8, 9 and E-PZ-5, 1, 4 respectively) (Figure 1B), and LNCaP, PC-3 and 
DU-145 cancer cell lines and PrEC normal prostate epithelial cells (Figure 1C). These data 
are summarised in and Table 2.  
 Several non-matched tumour cultures displayed elevated co-repressor levels (>2- fold 
elevation) compared to the mean level in the 7 normal cultures  with SMRT being the most 
frequently elevated (7/12), with NCoR1 and Alien less frequently elevated (2 and 1 cultures, 
respectively). Amongst the primary cancer cultures and cell lines there was a trend towards 
increased SMRT mRNA levels in the least differentiated and/or androgen-independent cells. 
Thus 2 out 6 cancer cultures with Gleason score 3/3 had elevated SMRT mRNA whilst 3 out 
of 4 cultures with Gleason score of 4/3 and greater had elevated SMRT. Similarly both 
androgen-insensitive cell lines had elevated SMRT (Table 1). Despite the relatively large 
spread of the fold-differences changes in SMRT in all primary cancer cultures (0.4 to 31.6), 
compared to the normal cultures, the mean δδct for the cancer cultures (where reduced δδct 
values indicate elevated target gene mRNA transcript) was 9.92+/- 2.004 (SD) compared to 
the normal which was 11.28 +/- 1.02 (SD), reflecting the reduced variation in levels in the 
normal peripheral zone cultures (Figure 1A). These data were supported by the matched 
cancer and peripheral zone normal  cultures, each pair from the same donor, in which all 
cancers displayed elevated SMRT mRNA compared to the normal counterpart elevation (> 2-
fold) (Figure 1B).  Interestingly the spread of SMRT levels in all cancer cultures samples 
correlated very strongly with those of VDR (r = 0.85, p<0.0001). A similar elevation in 
SMRT mRNA levels was observed in PC-3 and DU 145 cells [(1.8-fold, (p<0.05), and 2.2-
fold, (p<0.05)], respectively compared to PrEC cells (Figure 1C). The levels of SMRT did not 
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correlate with VDR, as seen in the primary cancer cultures tumours, and all cancer cell lines 
had a significant reduction in the VDR expression compared to PrEC cells.  
 We compared these expression patterns with sensitivity to the antiproliferative actions 
of 1α,25(OH)2D3 in primary cultures and cell lines (Table 1). The two assays measure related 
aspects of cellular responses to 1α,25(OH)2D3. The ATP proliferation assay measures total 
cellular ATP after 4 days, whilst the colony assay measures growth of cells after 10 days by 
measuring the total mass of cells (protein) per dish. In previous studies we have established 
that both of these readouts are proportional to cell number and thus these assays whilst 
different, are readily comparable (Peehl et al. 1994; Rashid et al. 2001a). Reflective of this 
the ED50 of normal cultures in the two assays were comparable, which we attribute to 
1α,25(OH)2D3  having a pleiotropic set of actions regulating both cell cycle progression, 
proliferation and invasion (Polek et al. 2003; Blutt et al. 2000; Blutt et al. 1997; Schwartz et 
al. 1997).  Elevated SMRT in PC-3 and DU-145 correlated with their insensitivity to 
1α,25(OH)2D3 (ED50 > 100 nM). The same diversity of responsiveness was seen in a 
representative panel of primary cancer cultures compared to normal, and BPH cultures. For 
example, in colony formation assays the benign culture (E-BPH#1) had ED50 = 0.2 nM, 
which was comparable with the responses of the normal strains we have characterised 
previously (Peehl et al. 1994), whereas the cancer  cultures displayed a spectrum of 
sensitivities. This spectrum is typified by the cancer culture E-CA-7, where the cancer culture 
which is insensitive to 1α,25(OH)2D3  (ED50 > 100 nM), whereas its matched normal 
counterpart (E-PZ-5) is acutely sensitive (ED50 = 5 nM). Taken together these data suggest 
that resistance of prostate cancer cells to 1α25(OH)2D3 relates to increased co-repressor 
expression/activity.  We subsequently went on to examine if the elevated co-repressor levels 
could be targeted by co-treatment with HDAC inhibitors. 
 
TSA augments the antiproliferative action of 1α,25(OH)2D3   
The PrEC cells proliferate at approximately the same rate as the PC-3 cancer cells and yet 
PrEC cells display a very different and acute response to the antiproliferative action of 
1α,25(OH)2D3 (Figure 2A,B). We used PC-3 cells, as a 1α25(OH)2D3-insensitive cell line 
with increased co-repressor expression, to measure the effect of HDAC activity on the 
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antiproliferative sensitivity to 1α25(OH)2D3. Control cultures of PC-3 and PrEC cells had 
comparable dose-response sensitivities to treatment with TSA alone (data not shown) and 
therefore, we examined the effects on proliferation of a minimally active dose of TSA (15 
nM) alone and co-treatment together with escalating doses of 1α25(OH)2D3. The acute 
inhibition of proliferation of PrEC cells by 1α25(OH)2D3 alone was only affected  by TSA 
when exposed to low doses of 1α,25(OH)2D3 (0.01 nM) (Figure 2A).  By contrast, in PC-3 
cells the co-treatment resulted in strong additive effects with 100 nM 1α,25(OH)2D3  and 
additive effects at 10 and 1 nM (Figure 2B); this effectively reinstated the antiproliferative 
response of PC-3 cells to levels that were comparable to PrEC cells. These data reflect our 
previous data obtained in prostate cancer cell lines at a single doses of 1α,25(OH)2D3 in both 
liquid and semi-solid proliferation assays (Rashid et al. 2001a).  
 
Regulation of VDR and CYP24 in PC-3 cells co-treated with agents 
To examine the transcriptional effects of the co-treatment of agents we examined the 
induction of VDR and CYP24. The CYP24 gene is among the best-characterized and most 
profoundly regulated VDR target gene (Dwivedi et al. 2000). We and others have shown in 
prostate and breast cancer and leukaemia cell lines that CYP24 is modulated in a manner that 
is broadly inversely proportional to the antiproliferative action of 1α25(OH)2D3, and is in part 
responsible for regulating cellular sensitivity to 1α25(OH)2D3 (Miller et al. 1995; Rashid et 
al. 2001b; Ly et al. 1999). Similarly in the current study we found exuberant tumour-
enhanced CYP24 induction in primary cancer cultures treated with 1α,25(OH)2D3 (50 nM, 6 
hr) (Figure 3A). Therefore we examined CYP24 mRNA expression in PC-3 cells over time.  
Treatment with 1α,25(OH)2D3 alone resulted in a rapid and very large upregulation of 
CYP24 mRNA (6.9- fold by 1 h, p<0.01), which continued throughout the course of the 
treatment, resulting in the very significant 6600- fold increase seen at 7 h  (p<0.0001) (Figure 
3B).  By contrast, treatment with TSA alone resulted in a relatively modest effect on 
expression peaking at 7 h (3.7- fold), but in combination it very significantly suppressed the 
1α,25(OH)2D3-dependent induction. For example, the mRNA upregulation observed with 
1α25(OH)2D3 alone at 7 h was significantly suppressed to a mean fold increase of 1302 
(p<0.001). At subsequent time points the suppressive action of TSA was diminished. 
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 We reasoned that the significant induction of CYP24 was in part the consequence of 
direct and indirect responses to treatment. To investigate this further we used the same 
treatments in the presence and absence of de-novo protein synthesis using cycloheximide. A 
significant reduction in the induction of CYP24 was observed when cycloheximide was 
added, although this was most pronounced with 1α,25(OH)2D3 alone. Consistent with the 
time course data, six hours exposure to 1α,25(OH)2D3 alone resulted in a 3342 mean fold 
increase (p<0.0001) in CYP24 mRNA expression (Figure 3C). However this was greatly and 
significantly suppressed (p<0.0001) to an 85-fold increase in cells co-treated with 
1α,25(OH)2D3 and cycloheximide. The effect of 1α,25(OH)2D3 was significantly suppressed 
further by co-treatment of both cycloheximide and TSA resulting in only a 4.4-fold increase. 
 Taken together, these data suggest a network of transcriptionally regulated co-factors 
that act in concert to modify the responses to 1α,25(OH)2D3. This does not appear to include 
the receptor as there were no significant effects on VDR expression with either single or 
combined treatments over the same 12 hr time course (data not shown).  
 
Identification and regulation of genes in PC-3 cells co-treated with 1α25(OH)2D3 plus  
TSA. 
To characterise more fully the transcriptional effects of the co-treatment of agents we 
undertook cDNA microarray analyses in PC-3 cells. A number of genes were identified that 
have been demonstrated to be targets for these agents by other workers. A well known 
established VDR target gene is the CDKI, p21(waf1/cip1)  (Liu et al. 1996) and supportively this 
was modulated in the 1α25(OH)2D3 alone treatment group (2.1- fold), however, this was 
unaffected by co-treatment with TSA (data not shown). This supports our previous study that 
indicated that this gene was not co-ordinately modulated by the co-treatment of 1α25(OH)2D3 
and TSA (Rashid et al. 2001a). Similarly TSA at higher concentrations than used in the 
current study is a potent inducer of apoptosis (Hirose et al. 2003a; Yamashita et al. 2003) and 
in the current study we found Bcl-2 down-regulated 0.48- fold by TSA treatment alone, which 
was unaffected by the co-treatment (data not shown). 
For subsequent studies we focussed on genes that appeared to be co-ordinately 
regulated by the combined treatments, and have established roles in regulating proliferation, 
differentiation and apoptosis. We identified 8 genes (out of 1176) that demonstrated co-
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operative, additive increases in expression after 6 h exposure to combined TSA and 
1α25(OH)2D3 (Table 2).  These genes included those that have roles in controlling apoptosis 
and proliferation [GADD45α (Jin et al. 2001),  Cyclin K (Mori et al. 2002)], and 
differentiation and/or adhesion [MAPK-APK2 (Alsayed et al. 2001; Wang et al. 2000), VE-
Cadherin (DeFouw & DeFouw 2000)].  For example, expression of GADD45α in 
1α25(OH)2D3- or TSA-treated PC-3 cells had a mean adjusted intensity (∆MAI)  of 434 and 
381, respectively, whereas co-treatment resulted in a ∆MAI of 6926 (Table 2).  From our 
preliminary validation studies we chose to focus on MAPK-APK2 and GADD45α  as these 
have been shown to be gene targets for nuclear receptor action (Alsayed et al. 2001; Wang et 
al. 2000; Akutsu et al. 2001).  
Real-Time RT-PCR over a 12 hr time course in PC-3 cells confirmed that MAPK-
APK2 mRNA was readily detected in control cells, reflecting the relatively strong control 
signal on the cDNA microarray, and was significantly higher than GADD45α mRNA levels 
(11.4-fold greater, p<0.001). This was reflected by the lack of a basal GADD45α signal 
detected on the cDNA microarray and hence no fold change could be calculated (Table 2). 
1α,25(OH)2D3 alone had limited effect on MAPK-APK2 mRNA expression with a modest 
1.3- fold increase after 6 h (Figure 4A). In contrast TSA alone produced an acute induction of 
2.3- fold increased mRNA expression at 4 h (p<0.001). Co-treatment with 1α,25(OH)2D3 and 
TSA resulted in a sustained window of MAPK-APK2 upregulation, which  was maintained 
for several hours to approximately 8 hrs post-treatment (Figure 4A). SB203580 is a highly 
specific inhibitor of p38 that blocks the activation of MAPK-APK2. Importantly SB203580 
had no effect on cell growth when used alone or in combination with either agent separately 
(Figure 4B and data not shown), but abrogated the capacity of TSA to sensitise PC-3 cells to 
the antiproliferative actions of 1α,25(OH)2D3 (Figure 4B). Taken together, these data suggests 
that the antiproliferative activity of combined TSA plus 1α,25(OH)2D3 is dependent on the 
sustained re-expression and activation of MAPK-APK2. 
 In some respects the pattern of GADD45α  mRNA expression in response to 
1α,25(OH)2D3 mirrored that of MAPK-APK2.  1α,25(OH)2D3 alone resulted in the steady 
accumulation of GADD45α mRNA after 3 h, peaking at 2.4- fold increase relative to control. 
TSA induction occurred between 4 and 6 hr post treatment with a significant mean fold 
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increase compared to control of 3.1 after 4 h (p<0.0001) (Figure 5A). However, as in the case 
of MAPK-APK2, the combined treatment sustained a window of increased expression at a 
level that was higher than the peak responses to either treatment alone (for example, 
1α,25(OH)2D3 1.0- fold, TSA 1.6- fold and co-treatment 4.3- fold, at 7 h). Consistent with 
this sustained pattern of mRNA expression, Western immunoblot analysis confirmed the 
increased expression of GADD45α protein most clearly following 9 h exposure to combined 
1α,25(OH)2D3 and TSA, but not to either agent alone (Figure 5B). Data at earlier time points 
did not show co-operative changes in protein (data not shown). 
 
Targeted silencing of SMRT with siRNA 
 To support further the central role of SMRT in distorting transcriptional effects and 
therefore the antiproliferative actions of 1α,25(OH)2D3,  we used a siRNA approach to reduce 
SMRT mRNA in PC-3 cells. The Q-RT-PCR primers and probes which detected SMRT 
mRNA levels were 3’ of the region targeted by the SMRT siRNA and therefore we were able 
to measure the effects of siRNA treatment at the mRNA level. These studies resulted in a 
mean 0.04 fold reduction in SMRT mRNA levels at 72 hr post-treatment (Figure 6A). Cells 
were then dosed with 1α,25(OH)2D3 and the induction of GADD45α  measured. Supportively 
in cells where SMRT levels were reduced, but not mock treated (GFP) cultures, GADD45α 
became very highly responsive to 1α,25(OH)2D3  treatment (Figure 6B). 
 
Dysregulation of VDR target genes in matched primary cultures 
To examine the significance of the differential gene responsiveness observed in PC-3 cells, 
we examined CYP24 and GADD45α mRNA induction in response to 1α,25(OH)2D3  
treatment (50 nM, for 6 hr) in three primary tumour cultures (E-CA-7, E-CA-8 and E-CA-14) 
compare to their matched peripheral zone cultures (E-PZ-5, E-PZ-1, and E-PZ-4 
respectively).  Initially we characterised the basal expression of the VDR, the three co-
repressors and the target genes CYP24 and GADD45α. All three tumour cultures displayed 
elevated SMRT compared to their matched normal counterpart and in cultures E-CA-7 and E-
CA-14 this was matched by elevated VDR levels (Figure 1B). E-CA-7, E-CA-8 and E-CA-
14) cultures displayed repressed levels of GADD45α relative to their matched normal 
controls (0.5-, 0.02- and 0.09- fold decrease, respectively). This was complemented by 
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elevated basal levels of CYP24 in the E-CA-7 and E-CA-14 cultures of 3.2- and 2.3-fold, 
respectively. Subsequently we examined the regulation of CYP24 and GADD45α in response 
to 1α,25(OH)2D3 (50 nM) (Figure 7 A,B). Upon treatment with 1α,25(OH)2D3  the tumour 
cultures displayed distorted responses with simultaneous enhancement of CYP24 and 
repression of GADD45α induction. CYP24 induction in the E-CA-7 cancer primary culture 
was approximately twice that seen in the normal counterpart peripheral zone (984- and 567- 
fold, respectively); enhancement of induction was also seen in the E-CA-8 and E-CA-14. By 
contrast, GADD45α was not modulated in the tumour culture but was (2.6-fold) in the 
peripheral zone normal cells (E-PZ-5). Similar dysregulation was seen in the other matched 
cultures. Interestingly E-CA-7, was essentially insensitive to 1α,25(OH)2D3  (ED50 > 100 nM) 
whereas its normal counterpart E-PZ-5, was acutely responsive (Table 1). Taken together 
these data support the concept of elevated SMRT co-repressor levels resulting in promoter-






The active metabolite of vitamin D, 1α,25(OH)2D3, is readily able to initiate gene 
transactivation and acutely regulate proliferation of normal prostate, breast and colon 
epithelial cells and myeloid CD 34 positive precursors (Konety et al. 1996; Zinser et al. 2002; 
Tong et al. 1998; Ratnam et al. 1996; Rashid et al. 2001b). By contrast, cancer and leukemic 
cell lines from these tissues display a spectrum of sensitivities including complete 
insensitivity to 1α,25(OH)2D3, irrespective of VDR expression (Campbell et al. 1997; Palmer 
et al. 2001; Kubota et al. 1998; Munker et al. 1986). The central hypothesis of the current 
study is that this apparent hormonal insensitivity is not determined solely by a linear 
relationship between the levels of 1α,25(OH)2D3 and the VDR, but rather epigenetic events 
skew the responsiveness to selectively suppress responsiveness of target gene promoters. 
We found frequently elevated co-repressor expression, most commonly involving 
SMRT, in malignant primary cultures and cell lines, with reduced 1α,25(OH)2D3 
antiproliferative response, but not normal or BPH cultures, indicating that the ratio of VDR to 
co-repressor is a more critical indicator of malignant status and 1α,25(OH)2D3 
responsiveness. We explored the significance of elevated co-repressor levels in both cancer 
cell lines and primary cultures. We reasoned that this lesion could be targeted by co-treatment 
of ligand (1α,25(OH)2D3) plus HDAC inhibitor (TSA) and supportively demonstrated that the 
1α,25(OH)2D3-response of the androgen-independent PC-3 cells was restored to levels 
indistinguishable from control PrEC cells, by co-treatment with low doses of TSA. This 
reversal of 1α,25(OH)2D3 insensitivity provided the opportunity to examine patterns of global 
acetylation and expression of target genes.  
In preliminary studies we have examined the global histone acetylation status after co-
treatment by extraction of total cellular histone from cells treated by single and combination 
treatments, and resolution on acid urea triton gels (Sommerville et al. 1993). The relatively 
low dose of TSA used (15 nM) readily increased global histone acetylation acetylation at all 
lysine residues examined (Histone H4 Lys16, Lys8, Lys12, Lys5, and Histone H3 Lys9 and 18, 
(data not shown)) but only altered expression of approximately 4% of genes on subsequent 
microarray studies. Similarly there was a lack of 1α,25(OH)2D3-induced acetylation (data not 
shown) despite its ability to induce a comparable number of genes. The combined treatment 
 20
did not alter global acetylation beyond the effect of TSA  alone. Collectively these data 
suggest that differences between global acetylation patterns do not reflect promoter-specific 
gene transcription.  
Microarray studies demonstrated that 1α,25(OH)2D3 plus TSA uniquely upregulated a 
group of ‘repressed’ gene targets associated with the control of proliferation and induction of 
apoptosis. GADD45α initiates cell cycle arrest, to facilitate DNA repair or apoptosis 
dependent upon the p53 status (Jin et al. 2003; Jin et al. 2001); upregulation of GADD45α 
when p53 function is abrogated induces a predominant apoptotic response (Jin et al. 2003). 
P53 function is abrogated in PC-3 cells and we have reported previously that co-treatment 
with 1α,25(OH)2D3 and TSA in these cells results in apoptosis, in the absence of any 
significant cell cycle changes (Rashid et al. 2001a).  Recently TSA has also been shown to 
induce GADD45α mRNA by a combination of stabilisation of transcription factors such as 
Oct1 on the promoter region (Hirose et al. 2003b) and thus in the current study this may well 
enhance further the activities of the VDR.  
Roles for both GADD45α and MAPK-APK2 have been demonstrated in cell lines that 
retain sensitivity to 1α,25(OH)2D3 signaling. For example, p38/MAPK-APK2 activation 
regulates 1α25(OH)2D3-induced HL-60 myeloid differentiation (Wang et al. 2000) and 
upregulation of GADD45α is a functional part of the antiproliferative action of EB1089 [an 
analogue of 1α,25(OH)2D3] in SCC25 squamous carcinoma cells (Akutsu et al. 2001) and 
1α,25(OH)2D3  in ovarian cancer cell lines(Jiang et al. 2003a). These studies and our own re-
expression data highlight these targets as key in mediating the antiproliferative action of 
1α,25(OH)2D3. A siRNA approach demonstrated the significant role that SMRT plays in 
regulating this response, with its repression resulting in profound enhancement of the 
induction of GADD45α in response to 1α,25(OH)2D3. These data support a central role for 
elevated SMRT levels in suppressing the induction of key target genes resulting in loss of 
sensitivity to  the antiproliferative action of 1α,25(OH)2D3.  
Target gene induction was measured by time course studies using highly sensitive Q-
RT-PCR which revealed distinct and relatively acute increases and decreases in mRNA levels. 
Co-treatment of 1α,25(OH)2D3  plus TSA generates temporal windows where the equilibrium 
point of gene transactivation is shifted to favour a more transcriptionally permissive 
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environment. This is limited by a number of processes including the nuclear receptor 
proteosomic turn-over (Reid et al. 2003a) and the metabolism of both agents (Yoshida et al. 
1995). The induction of CYP24, which encodes the 1α,25(OH)2D3-metabolising enzyme 
25(OH)D3-24-hydroxylase, is suppressed by the co-treatment and thus one contributory factor 
to the increased antiproliferative potency of the combination of 1α,25(OH)2D3 plus TSA 
treatment may be the greater availability of 1α,25(OH)2D3. However, CYP24-resistant 
analogs of 1α,25(OH)2D3 are not as inhibitory as 1α,25(OH)2D3  plus TSA, and in turn, we 
have demonstrated that their potency can be enhanced further by co-treatment with TSA 
(Rashid et al. 2001a). Thus, although ligand availability may be elevated, chromatin 
remodelling to allow VDR access to other promoters appears more influential.  
Suppression of promoter responsiveness is target gene- specific as exuberant induction 
of CYP24 occurred in PC-3 cells despite a suppression of GADD45α and MAPK-APK2 
response. Similarly the microarray analyses also identified a group of 39 genes modulated 
readily by 1α,25(OH)2D3 alone, many of which had no clear antiproliferative function, such 
as Cyclin B1, C-Myc, MCM7 DNA replication licensing factor and PCNA. Furthermore, co-
treatment with TSA suppressed the upregulation of CYP24 and many of the 1α,25(OH)2D3- 
responsive gene targets. For example, treatment of cells treated with 1α25(OH)2D3 alone 
resulted in a ∆MAI with PCNA of 20505 which was suppressed by the addition of TSA to 
3954 (data not shown). Intriguingly, co-treatment with cycloheximide suppressed the 
induction of CYP24; a similar suppression has been observed recently in different cell types 
(Zierold et al. 2002). By contrast upregulation of MAPK-APK2 and GADD45α by TSA and 
1α,25(OH)2D3 was unaffected, supporting a direct role for VDR in their regulation. Others 
have demonstrated a  co-operative interaction between VDR and Ets-1 on the CYP24 
promoter resulting in stimulation of gene responsiveness by upstream Ras (Dwivedi et al. 
2000; Dwivedi et al. 2002).  Thus, increased oncogenic Ets signalling may explain the 
paradoxical enhanced 1α,25(OH)2D3-dependent upregulation of CYP24 observed in cancer 
cells, and support the concept that high basal or inducible levels of CYP24 are transforming 
(Albertson et al. 2000).  
Work in primary prostate cultures has extended beyond cancer cell lines the concept 
that enhanced co-repressor action selectively suppresses the responsiveness of key 
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antiproliferative target gene promoters. We found significant and common elevation of SMRT 
in tumour cultures, and using matched tumour and normal peripheral zone culures we were 
able to demonstrate the promoter-specific dysregulation of CYP24 and GADD45α  observed 
in the cancer cell lines.  
The ability of the VDR target genes to respond differentially reflects both the different 
arrangement and sequence of VDRE amongst VDR target genes and the number of different 
apo and holo complexes which are assembled upon them. It has been proposed that a specific 
subset of VDRE (IP9) are more commonly associated with genes that mediate growth arrest 
and apoptosis (Quack & Carlberg 1999; Danielsson et al. 1997). Furthermore IP-9- type 
response elements have been shown to associate with the co-repressors NCoR1 or SMRT 
(Polly et al. 2000).  Taken together, these findings and our data support a model whereby 
elevated SMRT increases the prevalence of repressive complexes such as SMRT-HDAC3, 
which associate with the promoter/enhancer regions of key antiproliferative target genes 
thereby sustaining local histone deacetylation, and shifting the equilibrium point of gene 
activation resulting in reduced sensitivity to ligand. 
 The primary cultures used in the study were established from patients with organ-
confined disease who had not undergone hormonal manipulation and therefore elevation of 
SMRT probably occurs relatively early in disease progression, and is sustained through 
disease progression as a similar elevation was observed in cell lines derived from metastatic 
lesions. Thus this lesion may provide therapeutic opportunities for different stages of disease. 
Epigenetic repression in prostate cancer cells by elevated SMRT will potentially impact on 
multiple members of the nuclear receptor superfamily, such as the retinoic acid receptors, 
peroxisome proliferator-activated receptors and other adopted orphan receptors, resulting in 
reduced sensitivity to a wide range of dietary-derived macro- and micronutrient ligands. 
Therefore individual molecular profiling of early stage cancer disease may identify 
individuals with more aggressive disease, and those whose disease may be controlled by 
chemoprevention strategies. Current therapeutic strategies for prostate cancer involve a 
combination of radiotherapy or and radical prostatectomy, and eventually androgen ablation. 
These therapies are aggressive, with many side-effects and ultimately the cancer cells escape 
this control and androgen-independent tumours predominate which are invariably lethal. The 
current study has also highlighted the potential to establish novel chemotherapies centred 
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around HDAC inhibitors such as butyrate derivatives, TSA, and suberoylanilide hydroxamic 
acid  (SAHA) (Cohen et al. 2002; Zhu & Otterson 2003; Wang et al. 2004), in combination 
with potent dietary-derived compounds, to deliver a more focused and sustained ‘anticancer’ 




Figure 1: Fold elevation of nuclear co-repressor mRNA levels in prostate primary 
cancer cultures and cell lines. Panel A VDR and co-repressor mRNA levels measured by Q-
RT-PCR in primary cultures of cancers (E-CA-1, 2, 3, 4, 5, 6, 9, 10, 11, 12, 15, mean age of 
55.5), benign prostatic hyperplasia (E-BPH-1, E-BPH-2, average age 61 ) compared to the 
mean of seven normal peripheral zones cultures (E-PZ-1 to 7, mean age of 55). Total mRNA 
was isolated from cultures in mid-exponential phase, reverse transcribed and the target genes 
amplified in triplicate according to the Material and Methods. Panel B. VDR and co-repressor 
mRNA levels measured by Q-RT-PCR in three matched cancer (E-CA-7, E-CA-8 and E-CA-
14) compared to three normal matched peripheral zone cultures (E-PZ-5, E-PZ-1, and E-PZ-4 
respectively) as above. Panel C. VDR and SMRT, Alien, and NCoR1 co-repressors were 
measured in prostate cancer cell lines and compared to PrEC cells. Total mRNA was isolated 
from triplicate cultures in mid-exponential phase, reverse transcribed and the target genes 
amplified in triplicate according to the Material and Methods. *p < 0.05. 
 
Figure 2: Restoration of 1α,25(OH)2D3 antiproliferative signalling in PC-3 cells by 
co-treatment with TSA. PrEC cells (Panel A) and PC-3 cells (Panel B) and were plated into 
96 well plates and treated with TSA alone, (15nM) or in combination with a range of 
concentrations 1α25-(OH)2D3. After 96 hr, with a re-dose after 48 hr, total ATP was 
measured according to the Materials and Methods. Additive (Add) and Strong Additive (St. 
Add) interactions were defined according to the Materials and Methods. Each data point 
represents the mean of three separate experiments undertaken in triplicate wells+/- S.E.M.   
 
Figure 3:  Regulation of CYP24. Panel A. Normal peripheral zone and tumour cultures 
were treated with 50 nM 1α,25(OH)2D3  for 6 hr, or left untreated (control), and total mRNA 
isolated, reverse transcribed and CYP24 amplified and the fold increase calculated according 
to the Material and Methods. Panel B Regulation of CYP24 in response to 1α25-(OH)2D3 
(100 nM) and TSA (15 nM) either alone or in combination.  2x104/cm2 cells plated into 6 well 
plates and allowed to grow for 36 hours to ensure that cells were in mid-exponential phase. 
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Total RNA was isolated after the indicated time periods, reverse transcribed and CYP24 
amplified according to the Material and Methods. Each data point represents the mean of 
three separate experiments amplified in triplicate wells. 1α25-(OH)2D3 treatment was 
significantly greater that any other at all time points as indicated. Combined treatments that 
were significantly less than 1α25-(OH)2D3 treatment are indicated  *p < 0.05,  **p < 0.001   
***p<0.0001, ****p<<0.0001. Panel C. Real Time RT-PCR was used to measure the 
regulation CYP24 in response to 1α25-(OH)2D3 (100 nM) and TSA (15 nM) either alone or in 
combination, in the presence or absence of cyclohexamide (CHX, 20µg/ml).  Triplicate sets of 
2x104/cm2 cells were plated into 6 well dishes and allowed to grow for 36 hours. Total RNA 
was isolated after 6 hr exposure to the indicated treatments, reverse transcribed and the target 
genes were amplified according to the Material and Methods. Each data point represents the 
mean of three separate experiments undertaken amplified in triplicate wells. Combined 
treatments that were significantly greater than either agent alone, and the effect of CHX, are 
indicated  *p < 0.05,  **p < 0.001   ***p<0.0001.  
 
Figure 4: Regulation and activity of MAPK-APK2 in PC-3 cells. Panel A. Q-RT-PCR 
was used to measure the regulation of MAPK-APK2 in response to 1α25-(OH)2D3 (100 nM) 
and TSA (15 nM) either alone or in combination.  2x104/cm2 cells were plated in 6 well 
dishes and allowed to grow for 36 hours to ensure that cells were in mid-exponential phase. 
Total RNA was isolated after the indicated time periods, reverse transcribed and MAPK-
APK2 amplified according to the Material and Methods. Each data point represents the mean 
of three separate experiments amplified in triplicate wells. Combined treatments that were 
significantly greater than either agent alone are indicated  *p < 0.05. Panel B. PC-3 were 
plated into 96 well plates (2x103/well) cells and treated with either 1α25-(OH)2D3 (100 nM), 
TSA (15 nM) or SB203580 (10 µM) either alone or in combination. After 96 hr, with a re-
dose after 48 hr, total ATP was measured using a luciferase-dependent method according to 
the Materials and Methods and compared to untreated control, as a marker of proliferation. 
Each data point represents the mean of three separate experiments undertaken in triplicate 
wells +/- S.E.M. 1α25-(OH)2D3 plus TSA plus SB203580 is significantly less inhibitory than 
1α25-(OH)2D3 plus TSA (*p<0.05) 
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Figure 5:  Regulation of GADD45α  mRNA and protein in PC-3 cells. Panel A Q-
RT-PCR was used to measure the regulation of GADD45α mRNA in response to 1α25-
(OH)2D3 (100 nM) and TSA (15 nM) either alone or in combination.  2x10
4/cm2 cells were 
plated in 6 well dishes and allowed to grow for 36 hours to ensure that cells were in mid-
exponential phase. Total RNA was isolated after the indicated time periods, reverse 
transcribed and GADD45α amplified according to the Material and Methods. Each data point 
represents the mean of three separate experiments amplified in triplicate wells. Combined 
treatments that were significantly greater than either agent alone are indicated  *p < 0.05 
Panel B Parallel T75 flasks seeded at the same density were exposed to 1α25-(OH)2D3 (100 
nM) and TSA (15 nM) either alone or in combination and total protein was isolated after 9 hr.  
Expression of GADD45α was determined by Western immunoblot analysis. The position of 
GADD45α is indicated at the left of the panel.  Blots were subsequently stripped and re-
probed for β-actin 
 
Figure 6:  SiRNA targeted towards SMRT results in enhanced induction of 
GADD45α. 22mer dsRNA targeted towards either SMRT or green fluorescent protein (GFP) 
as a control was prepared as described in Materials and Methods. PC-3 cells (2x105) were 
plated into 24 well plates, transfected and after 72 hr they were subsequently dosed with 
1α,25(OH)2D3  (100 nM) or left untreated (control) for a further 6 hr, and total mRNA was 
extracted, reverse transcribed. Panel A The effects of the above treatments on the basal levels 
of SMRT were measured on cells untreated with 1α,25(OH)2D3. Panel B The effect of 
reduced SMRT mRNA was measured on the induction of GADD45α. Each data point 
represents the mean of two separate experiments amplified in triplicate wells. 
 
Figure 7:  Dysregulation of VDR target genes in primary cultures of matched pairs 
of tumour and peripheral zone. Primary tumour and matched normal peripheral zone 
cultures form the same donor were cultured and exposed to 1α,25(OH)2D3  (50 nM) for 6 hr 
or left untreated (control) and total RNA was extracted, reverse transcribed and the regulation 
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ED50  (nM) SMRT  levels 
(fold 
elevation) 
PrEC 34 N 10a 1 
LNCaP 50 AR +ve 100a 0.3 
PC-3 62 AR –ve >100a 1.8 
DU-145 69 AR –ve >100a 2 
E-PZ-1  52 N 5b 1.0 
E-PZ-2 50 N Nd 1.1 
E-PZ-3 59 N Nd 0.9 
E-PZ-4 61 N Nd 0.9 
E-PZ-5 45 N 5b 1.2 
E-PZ-6 62 N Nd 1.2 
E-PZ-7 56 N Nd 0.8 
E-BPH-1  58 N 0.2b 0.8 
E-BPH-2  64 N 1b 1.1 
E-CA-1 50 3 / 3 Nd 0.5 
E-CA-2 50 3 / 3 Nd 0.7 
E-CA-3 64 3 / 3 Nd 1.5 
E-CA-4 54 3 / 3 Nd 2.1 
E-CA-5 64 3 / 3 Nd 3.8 
E-CA-6 69 3 / 3 Nd 4.4 
E-CA-7 45 80% (3), 
20% (4) 
>100b 3.2 
E-CA-8 52 70% (3), 
30% (4) 
Nd 3.3 
E-CA-9 68 3 / 4 Nd 0.5 
E-CA-10 70 3 / 4 Nd 0.4 
E-CA-11 62 3 / 4 Nd 2.4 
E-CA-12 62 4 / 3 1b 4.3 
E-CA-13  54 40% (4), 
30% (3), 
20%  - IDC 
Nd 0.4 
E-CA-14 31 60% (4), 
20% (3) 
Nd 17.8 
E-CA-15 51 100% (5) Nd 31.6 
Table 2: Characteristics and responsiveness to 1α,25(OH)2D3  of cell lines and 
primary cultures.  N = normal prostate epithelial cells,  AR = androgen receptor, ED50 = 
estimated dose of 1α,25(OH)2D3  (nM) required to inhibit cell proliferation as measured 
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GADD45α Forward primer AAGACCGAAAGGATGGATAAGGT 
GADD45α Reverse primer GTGATCGTGCGCTGACTCA 
GADD45α Probe TGCTGAGCACTTCCTCCAGGGCAT 
MAPKAPK2 Forward primer GCCTGCTGATTGTCATGGAA 
MAPKAPK2 Reverse primer TGGTCTCCTCGATCCTGGAT 
MAPKAPK2 Probe TTTGACGGTGGAGAACTCTTTAGCCGT 
CYP24  Forward primer CAAACCGTGGAAGGCCTATC 
CYP24  Reverse primer ACTTCTTCCCCTTCCAGGATCA 
CYP24  probe ACTACCGCAAAGAAGGCTACGGGCTG 
Alien Forward primer CCTCATCCACTGATTATGGGAGT 
Alien Reverse primer CATCATAATTCTTGAAGGCTTCA 
Alien Probe CCCTCAAGTGCATTTTACCACCACATTCTCT 
NCoR1Forward primer TGAAGGTCTTGGCCCAAAAG 
NCoR1Reverse primer TTTGTCTTGATGTTCTCATGGTA 
NCoR1Probe CTGCCACTGTATAACCAGCCATCAGATACCA 
SMRT Forward primer CACCCGGCAGTATCATGAGA 
SMRT Reverse primer CGAGCGTGATTCCTCCTCTT 
SMRT Probe CTTCCGCATCGCCTGGTTTATT 
VDR Forward Primer CTTCAGGCGAAGCATGAAGC 
VDR Reverse Primer CCTTCATCATGCCGATGTCC 
VDR Probe AAGGCACTATTCACCTGCCCCTTCAA 
 
 



















Table 3: Co-operative regulation of gene expression patterns by co-treatment with TSA 
and 1α,25(OH)2D3 Table of fold differences (Fold) and change in the mean adjusted intensity 
(∆MAI) for target genes that were co-operatively regulated by the co-treatment of agents,  
compared to control. From each of the treatments the fold and ∆MAI was calculated from the 
mean of the two experiments. Only genes that were reported as modulated in the same manner 
in both experiments were included in the results. Repeat experiments involved stripping the 
membranes (which were checked to ensure zero signal) and reprobing with radiolabelled 
probes prepared from repeat treatments of cells.  
Nc, fold change not calculated. 
 





Fold ∆MAI Fold ∆MAI Fold ∆MAI
DNA-binding protein 
inhibitor ID-1; Id-1H 
D13389 3.8 16038 2.2 16087 6.6 26246 
Cyclin K AF06515 1.2 623 1.5 2756 8.9 15752 
MAP kinase-activated 
protein kinase 2 (MAPK-
APK2) 
U12779 1.4 7352 1.5 7683 2.7 20143 
ras-related C3 botulinum 




Nc 6665 Nc 6965 Nc 14965 
Zyxin + zyxin-2 X94991; 
X95735 
1.5 2959 0.8 3109 3.5 13898 
Growth arrest & DNA-
damage-inducible protein 
(GADD45);  
M60974 Nc 434 Nc 382 Nc 6926 
beta catenin (CTNNB) X87838; 
Z19054 
Nc 1231 Nc 1560 Nc 2427 
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